Philogen Announces Publication of PET Clinical Data with Proprietary Ultra-high Affinity FAP-targeting Small Molecule Ligand (OncoFAP)

Siena, Italy, Jan. 7 (Korea Bizwire) - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, announces that its wholly-owned Swiss subsidiary, Philochem AG, has co-authored a new translational study on 68Ga-OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper, entitled “Translational imaging of the fibroblast activation [...]